Myleran

দেশ: অস্ট্রেলিয়া

ভাষা: ইংরেজি

সূত্র: Department of Health (Therapeutic Goods Administration)

সক্রিয় উপাদান:

Busulfan

থেকে পাওয়া:

Aspen Pharmacare Australia Pty Ltd

শ্রেণী:

Medicine Registered

তথ্য লিফলেট

MYLERAN
®

_busulfan_
CONSUMER MEDICINE INFORMATION (CMI)

WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about MYLERAN tablets.
It does not contain all of the available
information. It does not take the
place of talking to your doctor or
pharmacist.
All medicines have risks and
benefits. Your doctor has weighed
the risks of you taking MYLERAN
tablets against the benefits this
medicine is expected to have for you.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE, ASK YOUR
DOCTOR.
KEEP THIS LEAFLET WITH THE MEDICINE.
You may need to read it again.
WHAT MYLERAN IS
USED FOR
MYLERAN contains busulfan as the
active ingredient. It belongs to a
group of medicines called cytotoxics.
MYLERAN is used to treat certain
blood disorders.
It works by reducing the amount of
certain types of blood cells in your
body.
ASK YOUR DOCTOR IF YOU HAVE ANY
QUESTIONS ABOUT WHY MYLERAN
HAS BEEN PRESCRIBED FOR YOU.
Your doctor may have prescribed it
for another purpose.
This medicine is only available with
a doctor's prescription.
There is no evidence that it is
addictive.
BEFORE YOU TAKE IT
_WHEN YOU MUST NOT TAKE IT_
DO NOT TAKE MYLERAN IF YOU
HAVE EVER HAD AN ALLERGIC REACTION
TO:
•
busulphan
•
any of the tablet ingredients listed
at the end of this leaflet.
Symptoms of an allergic reaction
may include shortness of breath,
wheezing or difficulty in breathing;
swelling of the face, lips, tongue or
any other parts of the body; rash,
itching or hives on the skin.
DO NOT TAKE MYLERAN IF YOU ARE
PLANNING TO BECOME PREGNANT OR
FATHER A CHILD UNLESS YOU AND YOUR
DOCTOR HAVE DISCUSSED THE RISKS AND
BENEFITS INVOLVED.
MYLERAN may harm eggs and
sperm. Reliable contraceptive
methods must be taken to avoid
pregnancy whilst you or your partner
is taking this medicine.
DO NOT TAKE MYLERAN IF YOU ARE
PREGNANT UNLESS YOU AND YOUR
DOCTOR HAVE DISCUSSED THE RISKS AND
BENEFITS INVOLVED.
It may affect your developing baby if
you take it during pregnancy.
DO NOT TAKE THIS MEDICINE WHILST
BREAST FEEDING.
DO NOT TAKE I

পণ্য বৈশিষ্ট্য

PRODUCT INFORMATION 

MYLERAN TABLETS 

NAME OF THE DRUG:  

The chemical name for busulfan is 1,4-butanediol dimethanesulfonate,
it has a molecular weight of 
246.29, it's molecular formula is C
6
H
14
O
6
S
2
, CAS No.: 55-98-1 and the chemical structure is:  

Myleran tablets contain 2 mg busulfan.  

DESCRIPTION:  

Busulfan is a white, crystalline powder. It is very slightly soluble
in water and ethanol (96%), freely 
soluble in acetone, in acetonitrile and in chloroform. It has a
melting point of 115-118°C.  

Each Myleran tablet also contains anhydrous lactose,
pregelatinised maize starch, magnesium 
stearate, hypromellose, titanium dioxide and glycerol triacetate.  

ACTIONS:  

Myleran in small daily doses of 4 mg, administered orally,
depresses both normal and abnormal 
myeloid tissue. It is this property which has proved to be of value
in the treatment of a proportion 
of cases of chronic myelogenous leukaemia. The drug is more selective
than nitrogen mustard or 
the folic acid antagonists in its effect on the myeloid cells and may
be somewhat safer in use; 
certain patients have received daily doses of 4 mg for as long as a
year. In such doses, although it 
depresses myelopoiesis, it has little effect upon the lymphocytes
and platelets, and side effects 
are absent.  

Larger doses, however, depress the platelet count and cause
haemorrhagic symptoms, and there 
is a danger of causing an irreversible depression of the bone marrow
which may not become 
obvious for 4 to 6 months. These effects show the necessity for
careful haematological control. 
The most favourable effects, seen in some cases of chronic
myelogenous leukaemia, are rise in 
the haemoglobin levels, a selective reduction or even
disappearance of immature myeloid cells 
from the blood, a reduction in the cellularity of the bone marrow, a
diminution in the size of the 
enlarged spleen, and pronounced subjective improvement.  

INDICAT